Drugs / PABINAFUSP ALFA
last change Feb 2023 re-read 2 minutes ago

PABINAFUSP ALFA

also known as JR-141

Protein / enzyme biologic

Developed for
mucopolysaccharidosis type 2
Investigated by
JCR Pharmaceuticals Co., Ltd.

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03128593 Mar → Oct 2017 mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03708965 Jan 2019 → Dec 2026 expected mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT03359213 Jul 2018 → Oct 2019 mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT04348136 Sep 2019 → Mar 2030 expected mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Active not recruiting No outcome recorded
Phase 2/3 NCT03568175 Aug 2018 → Feb 2020 mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT05594992 Feb 2023 → Feb 2028 expected mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Enrolling by invitation No outcome recorded
Phase 3 NCT04573023 Feb 2022 → Oct 2027 expected mucopolysaccharidosis type 2 JCR Pharmaceuticals Co., Ltd. Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as PABINAFUSP ALFA ChEMBL registry synonym — accepted as the source's own label CHEMBL4594565
Known as JR-141 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594992
6

NCT03708965

NCT04573023

NCT04348136

NCT03359213

NCT03128593

NCT03568175

Modality Protein / enzyme biologic “A novel IDS fused with anti-human transferrin receptor antibody (JR-141) has been shown to penetrate the BBB” PMID 30595526 Dec 2018
Route Intravenous “IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week” NCT03128593